 MINNEAPOLIS, July 02, 2021 GLOBE NEWSWIRE -- Panbela Therapeutics, Inc. Nasdaq: PBLA the Company or Panbela, a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the closing of its previously announced public offering of 3,333,334 shares of common stock of the Company at a price to the public of 3.00 per share, less underwriting discounts and commissions. 